Steven Cohen Aravive, Inc. Transaction History

Point72 Asset Management, L.P.

  • $36 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.29 - $2.46 $8,227 - $15,689
6,378 New
6,378 $12,000

Others Institutions Holding ARAV

# of Institutions
2
Shares Held
28.1K
Call Options Held
0
Put Options Held
0
View Full List

About Aravive, Inc.

ARAV Quotes by TradingView
  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email